Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | HX008 + Irinotecan |
Indication/Tumor Type | gastroesophageal junction adenocarcinoma |
Response Type | unknown |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | gastroesophageal junction adenocarcinoma | unknown | HX008 + Irinotecan | Phase II | Actionable | In a Phase II trial, CD274 (PD-L1)-positive gastric or gastroesophageal junction cancer patients treated with HX008 and Camptosar (irinotecan) achieved an objective response rate (ORR) of 38.5% (5/13), disease control rate (DCR) of 84.6% (11/13), median progression-free survival (mPFS) of 4.3 mo, and median overall survival (mOS) was not reached, compared to CD274 (PD-L1) negative patients with an ORR of 37.5% (3/8), DCR of 75% (6/8), mPFS of 5.0 mo, and mOS of 8.7 mo (PMID: 33060149; NCT03704246). | 33060149 |
PubMed Id | Reference Title | Details |
---|---|---|
(33060149) | HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial. | Full reference... |